Free US stock correlation to major indices and sector benchmarks for performance attribution analysis. We help you understand how your portfolio moves relative to broader market benchmarks.
ProQR Therapeutics N.V. Ordinary Shares (PRQR), a clinical-stage biotech firm focused on RNA-based therapies for rare genetic diseases, is trading at $1.82 as of April 6, 2026, marking a 6.55% gain in recent trading. This analysis evaluates current price action, sector context, key technical support and resistance levels, and potential near-term scenarios for the stock, with no recent earnings data available for the company as of this publication. The recent upward move comes amid mixed sentimen
Is ProQR (PRQR) Stock Good for Short Term | Price at $1.82, Up 6.55% - Expert Stock Picks
PRQR - Stock Analysis
4970 Comments
1251 Likes
1
Kentaro
Active Reader
2 hours ago
A great example of perfection.
π 233
Reply
2
Darquisha
Regular Reader
5 hours ago
As a working mom, timing like this really matters⦠missed it.
π 18
Reply
3
Anslem
Loyal User
1 day ago
I wish I didnβt rush into things.
π 94
Reply
4
Lener
New Visitor
1 day ago
How are you not famous yet? π
π 299
Reply
5
Leshawn
Expert Member
2 days ago
Comprehensive US stock backtesting and historical performance analysis to validate investment strategies before committing capital to any trading approach. We provide extensive historical data that allows you to test any trading idea before risking real money in the market. Our platform offers backtesting frameworks, performance attribution, and statistical analysis for strategy validation. Validate your strategies with our professional-grade backtesting tools and comprehensive historical data for better results.
π 34
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.